DotLab Expands Enrollment of Physicians in the DotEndo Early Access Program for its Non-Invasive Endometriosis Test at the 2018 American Society of Reproductive Medicine Scientific Congress & Expo

Published: Oct 09, 2018

DotLab is exhibiting and offering demos of DotEndo at their booth at ASRM 2018     

DENVER, Oct. 8, 2018 /PRNewswire/ -- DotLab, a personalized medicine company for women's health, is pleased to announce that the company will expand its enrollment of U.S. physicians into the Early Access Program for its non-invasive endometriosis test. DotLab made the announcement at the 2018 American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo. ASRM is the premier education and research meeting for reproductive medicine, and the 2018 conference is taking place from October 6-10 in Denver, Colorado. Throughout the conference, DotLab will be enrolling physicians at their booth, #980, where team members are offering product demos.

DotLab is commercializing the first-ever accurate, non-invasive endometriosis test, DotEndo, which measures disease-specific biomarkers to detect the presence of active endometriosis disease. Hundreds of patients have been assessed to date across retrospective and prospective studies evaluating the performance of the biomarkers relative to the gold standard for diagnosis, laparoscopic surgery. The Early Access Program, which includes a diverse set of fertility clinics across the United States, is currently for the company's saliva test.

"Approximately half of women undergoing IVF have endometriosis. If the disease is diagnosed and treated prior to IVF, women could have a better chance of getting pregnant," said Heather Bowerman, DotLab's Founder and Chief Executive Officer.

At the 2017 ASRM Scientific Congress & Expo, prospective study results were presented showing the performance data of DotEndo biomarkers. Endometriosis diagnoses were confirmed by laparoscopic surgeries, and the prospective study was recognized with the Endometriosis SIG Prize Paper award.

The discovery and development of DotEndo was led by Dr. Hugh Taylor, Chair of the Department of Obstetrics, Gynecology, and Reproductive Sciences at the Yale School of Medicine and Chief of Obstetrics and Gynecology at Yale-New Haven Hospital. Dr. Taylor gave a pre-Scientific Congress course on October 7th, 2018, entitled "Emerging Therapies for Endometriosis – 2018 and Beyond."

About DotLab: DotLab is a personalized medicine company that has been recognized by Goldman Sachs for entrepreneurship, the Business Times as a top female-led company, and as a technology to watch by the MIT Technology Review. For more information, please visit www.dotlab.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dotlab-expands-enrollment-of-physicians-in-the-dotendo-early-access-program-for-its-non-invasive-endometriosis-test-at-the-2018-american-society-of-reproductive-medicine-scientific-congress--expo-300727317.html

SOURCE DotLab

 

Back to news